Cargando…

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc

INTRODUCTION: Cenicriviroc (CVC), a once-daily, dual CCR5/CCR2 co-receptor antagonist, has completed Phase 2b development. CVC demonstrated favourable safety and similar efficacy compared with efavirenz (EFV) in Study 202 (NCT01338883); an ex vivo sub-analysis evaluated treatment effects on HIV entr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kramer, Victor, Hassounah, Said, Colby-Germinario, Susan, Mesplède, Thibault, Lefebvre, Eric, Wainberg, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Oral Presentation – Abstract O433
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224821/ https://www.ncbi.nlm.nih.gov/pubmed/25394040 http://dx.doi.org/10.7448/IAS.17.4.19531

Ejemplares similares

HIV entry blocked by maraviroc can cause an overestimation of viral load
por: Sloan, RD, et al.
Publicado: (2010)

Looking for Brugada in COVID-19 patients
por: Benali, M., et al.
Publicado: (2023)

Le score CURB-65 appliqué à la pneumonie COVID-19 : quel apport ?
por: Allouche, A., et al.
Publicado: (2023)

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014)

Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review
por: Hassounah, Said A., et al.
Publicado: (2016)

Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor
por: Quashie, Peter K., et al.
Publicado: (2015)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
por: Férir, Geoffrey, et al.
Publicado: (2011)

Integrase Strand Transfer Inhibitors in HIV Therapy
por: Mesplède, Thibault, et al.
Publicado: (2013)

Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study
por: Garcia, Federico, et al.
Publicado: (2014)

HIV in women
por: Mulcahy, F
Publicado: (2012)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
por: Mesplède, Thibault, et al.
Publicado: (2015)

Will LEDGIN molecules be able to play a role in a cure for HIV infection?
por: Mesplède, Thibault, et al.
Publicado: (2016)

First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN
por: Heera, Jayvant, et al.
Publicado: (2014)

HIV, co-morbidity and ageing
por: Reiss, P
Publicado: (2012)

Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy
por: Wainberg, Mark A, et al.
Publicado: (2015)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Life expectancy of HIV-1-positive individuals approaches normal conditional on response to antiretroviral therapy: UK Collaborative HIV Cohort Study
por: May, M, et al.
Publicado: (2012)

TB and HIV: how can we reduce mortality?
por: Lawn, S
Publicado: (2012)

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
por: Rusconi, S, et al.
Publicado: (2010)

What if HIV were unable to develop resistance against a new therapeutic agent?
por: Wainberg, Mark A, et al.
Publicado: (2013)

Currently available medications may not be sufficient for lifelong treatment of HIV
por: Jansson, J, et al.
Publicado: (2012)

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses
por: Pham, Hanh T., et al.
Publicado: (2016)

HIV drug resistance against strand transfer integrase inhibitors
por: Anstett, Kaitlin, et al.
Publicado: (2017)

HIV drug resistance surveillance in low- and middle-income countries: 2004 to 2010
por: Bertagnolio, S, et al.
Publicado: (2012)

Towards an HIV cure
por: Deeks, Steven
Publicado: (2014)

HIV epidemic in Russia and neighbouring countries
por: Pokrovskiy, Vadim
Publicado: (2014)

Review of life expectancy in people with HIV in settings with optimal ART access: what we know and what we don't
por: Sabin, C
Publicado: (2012)

The cascade of HIV care in Russia, 2011–2013
por: Pokrovskaya, Anastasia, et al.
Publicado: (2014)

HIV treatment 2020: what will it look like?
por: Gulick, Roy
Publicado: (2014)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Determinants of IL-6 levels during HIV infection
por: Borges, Álvaro H, et al.
Publicado: (2014)

Orphans of the HIV epidemic: the challenges from toddlerhood to adolescence and beyond
por: Lala, Mamatha M
Publicado: (2014)

The challenge: streamlining HIV treatment and care while improving outcomes
por: Clumeck, Nathan
Publicado: (2014)

Management of drug-resistant TB in patients with HIV co-infection
por: Meintjes, Graeme
Publicado: (2014)

HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M
por: Depatureaux, Agnès, et al.
Publicado: (2014)

A clinically useful risk-score for chronic kidney disease in HIV infection
por: Mocroft, Amanda, et al.
Publicado: (2014)

Regional differences in self-reported HIV care and management in the EuroSIDA study
por: Grønborg Laut, Kamilla, et al.
Publicado: (2014)

HIV, cyclophilins and nuclear entry: going under the radar
por: Towers, Greg
Publicado: (2011)

Does pregnancy increase the risk of ART-induced hepatotoxicity among HIV-positive women?
por: Huntington, Susie, et al.
Publicado: (2014)

Drug use, HIV, HCV and TB: major interlinked challenges in Eastern Europe and Central Asia
por: Kazatchkine, Michel
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ocsbgkldhsdoukmmjoupmr7ni6